Invokana® has been linked to life threatening side effects such as ketoacidosis. Get the facts to see if you have a viable case for compensation by talking to an Invokana injury lawyer at the Hollis Law Firm.
Type 2 diabetes, also called adult onset diabetes, affects about 27 million Americans. Type 2 diabetes occurs when the patient develops an insulin resistance. Insulin is a hormone that regulates the body’s conversion of the glucose we eat into energy and how much glucose is in our blood. During the beginning of adult onset diabetes, the pancreas produces an increased amount of insulin to attempt to deliver glucose to cells. As time goes on, the pancreas cannot keep up and the sugar builds up in the blood which sparks high blood sugar. To help the patient stabilize their blood sugar levels, sodium-glucose co-transporter (SGLT2) inhibitors were created. Johnson & Johnson pharmaceuticals created the SGLT2 inhibitor called Invokana®.
Invokana works to stop the reabsorption of glucose in the blood. In the kidneys, Invokana stops sugar from getting reabsorbed into the blood by inhibiting a protein called SGLT2. Once the sugar absorption is halted, the sugar gets secreted from the body during urination. The patient’s blood sugar levels are lowered as a result of eliminating the sugar from their system.
Why are patients seeking an Invokana injury lawyer?
Patients are seeking an Invokana injury lawyer because Invokana has been linked to the development of ketoacidosis. Ketoacidosis is a severe, life threatening condition when the patient’s ketone level in their blood becomes dangerously high and they may slip into a diabetic coma. To find a knowledgeable Invokana injury lawyer, speak to a member of the Hollis Law Firm. Here at the Hollis Law Firm, we have experience in helping those who have fallen victim to bad pharmaceutical drugs and offer risk-free legal consultations. To speak to an Invokana injury lawyer about your risk-free Invokana lawsuit consultation call 1-800-701-3672 or fill out the form located on this page.